Certuity LLC Takes Position in iShares Biotechnology ETF (NASDAQ:IBB)

Certuity LLC purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,435 shares of the financial services provider’s stock, valued at approximately $454,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IBB. Darwin Wealth Management LLC purchased a new stake in iShares Biotechnology ETF in the third quarter valued at approximately $29,000. Highline Wealth Partners LLC acquired a new stake in shares of iShares Biotechnology ETF in the third quarter valued at $30,000. HHM Wealth Advisors LLC grew its stake in shares of iShares Biotechnology ETF by 200.0% in the fourth quarter. HHM Wealth Advisors LLC now owns 225 shares of the financial services provider’s stock valued at $30,000 after buying an additional 150 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in iShares Biotechnology ETF during the 4th quarter worth about $33,000. Finally, Hager Investment Management Services LLC purchased a new position in iShares Biotechnology ETF during the 4th quarter valued at about $34,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Up 0.9 %

NASDAQ IBB opened at $135.47 on Thursday. The stock has a 50-day moving average of $135.88 and a two-hundred day moving average of $141.13. iShares Biotechnology ETF has a 1-year low of $123.60 and a 1-year high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were issued a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.